Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous human immunoglobulin in primary immunodeficiency (single-arm, multicenter)
ChiCTR2500111121Phase 3Completed
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune serum globulin in Immunogenetic disorder, common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoint: Annualised incidence rate of serious bacterial infection (SBI) events. Started Oct 2025; status: completed.
02
Drugs
immune serum globulin
03
Conditions
Immunogenetic disordercommon variable immunodeficiency (CVID)X-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on ChiCTR2500111121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111121.